In children presenting to the emergency department with a moderate acute asthma attack, does the addition of ipratropium bromide decrease hospital admission rate?

In children presenting to the emergency department with a moderate acute asthma attack, does the addition of ipratropium bromide, to currently accepted therapy (salbutamol and prednisolone) decrease hospital admission rate?

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612000829819

Enrollment

128

Registered

2012-08-07

Start date

2012-09-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

In this study we aim to look at the best treatment for children presentling to the emergency department with an acute episode of asthma. Specifically, we are interested in children who have moderate severity of their symptoms on arrival. The primary purpose of this study is to determine whether there is a decreased need for hospital admission in these children when they atre treated with inhaled ipratropium bromide (IIB), inhaled salbutamol (IS) and oral steroid , compared with patients treated with Inhaled salbutamol and oral steroid alone

Interventions

Intervention group: will receive standard care for moderate acute asthma. That is, salbutamol 6 puffs(100mcg per puff) via MDI/spacer x3 20 minutely over 1 hour for <20kg OR 12 puffs via same method for > 20kg. Plus 1mg /kg prednisolone, as syrup, before 2nd dose of salbutamol. They will also receive 4 puffs of ipratropium bromide(21mcg per puff) via MDI/spacer x3 20minutely for < 20kg and 8 puffs via same method for > 20kg. Ipratropoium will be given at same time as salbutamol.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

2 Years to 16 Years

Healthy volunteers

Inclusion criteria

Children aged >2 and < 16 years with a clinical diagnosis of acute moderate asthma exacrebation

Exclusion criteria

Children with mild or severe/life threatening asthma Children borne before 34 weeks of gestation Children suffering from following pathologies: chronic pulmonary diseases (examples: cystic fibrosis, bronchopulmonary dysplasia), congenital heart or lung disease, recurrent pulmonary inhalations, neuromuscular disease Immunocompromised children Children with confirmed pneumonia Children who have received corticosteroid within 24 hours of presentation and/or atrovent or ventolin with 3 hours of presentation Children for whom parent/carer refused to give informed consent Children who have had a previous episode of acute asthma requiring ICU admission/intervention, including treatment with magnesium

Outcome results